Latest

Merck files Keytruda for lung cancer, eyes first-line niche

Merck files Keytruda for lung cancer, eyes first-line niche

Genetic protein PD-L1 could have potential as a biomarker for a first-line treatment.

FDA takes unusual stance on ALS drug

FDA takes unusual stance on ALS drug

The FDA asked private biotech Genervon to release all available clinical trial data for its experimental ALS treatment.

Conflict-of-interest rules spur $23M investment

Conflict-of-interest rules spur $23M investment

Schools spent $23 million to bring conflict-of-interest policies in line with regulations aimed at ensuring federally funded research is unbiased.

J&J to pay $63M in Motrin case

A Massachusetts court upheld a 2013 decision that the drugmaker failed to provide sufficient risk information for Children's Motrin.

Five things for pharma marketers to know: Monday, April 20

Five things for pharma marketers to know: Monday, April 20

Teva eyes Mylan takeover; Keytruda shown to improve survival, shrink tumors in melanoma; ADHD abuse may follow grads into workforce.

Editor's Desk: And the researchers go wild

Editor's Desk: And the researchers go wild

Apple's ResearchKit could accelerate the pace at which industry approaches start-ups building products in the patient-facing part of health tech

Five things for pharma marketers to know: Friday, April 17

Five things for pharma marketers to know: Friday, April 17

The FDA approves generic Copaxone; AstraZeneca's experimental lung-cancer drug demonstrates that it can delay disease progression; PhRMA CEO John Castellani to step down

Bob Finkel launches 'agency alternative'

Bob Finkel launches 'agency alternative'

Kane & Finkel co-founder Bob Finkel launched a healthcare consultancy that will seek out limited-commitment projects.

Amgen motion to delay Neupogen biosimilar denied

Amgen's attempt to delay Zarxio was denied by a US District Court, which said the argument was speculative.

Five things for pharma marketers to know: Thursday, April 16

Five things for pharma marketers to know: Thursday, April 16

FDA approves Amgen heart failure drug; Pfizer halts breast-cancer drug trial over positive results; 30% of study participants asked docs about drug after seeing or reading an ad

FDA committee recommends label change for Onglyza

FDA committee recommends label change for Onglyza

Despite an FDA committee voting that AstraZeneca's diabetes medication carries an acceptable heart risk, analysts say a Merck study will determine the DPP-IV category's fate.

Biogen, PatientsLikeMe use Fitbit to better understand MS

Biogen, PatientsLikeMe use Fitbit to better understand MS

The drugmaker and patient network teamed up to establish a formal framework for deploying activity trackers for patients with MS and for capturing that data.

Novartis leukemia drug ups progression-free survival

Late-stage results show Arzerra patients have a median progression-free survival rate almost double that of chemotherapy-only patients.

Five things for pharma marketers to know: Wednesday, April 15

Five things for pharma marketers to know: Wednesday, April 15

An FDA panel said heart risks should be part of Onglyza's label; the OIG will examine generic price increases; Abbott said its OTC glucose meter will save patients money

J&J reports quarterly boost in drug sales

J&J reports quarterly boost in drug sales

The company reported $7.7 billion in pharma revenue in the first quarter despite a drop in overall sales and profit.

Agency Spotlight


The 2015 healthcare agency questionnaire, for firms hoping to be featured in the Top 100 Agencies issue, is live. Click here to be considered.

Email Newsletters